Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 10/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418755 | 0.84 | L3MBTL1 (0.75) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL834525 | 0.83 | L3MBTL1 (0.88) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL24396458 | 0.82 | L3MBTL1 (0.85) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL1334332 | 0.82 | L3MBTL1 (0.79) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL7461820 | 0.81 | GAA (0.86) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL18868405 | 0.81 | L3MBTL1 (1.00) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL15031340 | 0.81 | L3MBTL1 (0.70) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL28269832 | 0.81 | PKM (0.62) | L3MBTL1POLBRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL166144 | 0.81 | L3MBTL1 (0.70) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL27645980 | 0.80 | MAPT (0.72) | L3MBTL1GAAMAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | KALYPSYS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-6756388-B1 | HAVING PIPERIDINYL AND PHENOLIC FUNCTIONALITY; BONE LOSS; BREAST OR PROSTATE CANCER | PFIZER INC. | 2004-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194681-A1 | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | HDAC1, HDAC10, HDAC6 | L3MBTL1 4133/4885GAA 72/4885MAPT 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.